Novartis cuts PhII obesity candidate as it finalizes Sandoz spinoff

No­var­tis shelved a Phase II pro­gram it was test­ing for obe­si­ty-re­lat­ed dis­eases af­ter find­ing a lack of ef­fi­ca­cy, the phar­ma gi­ant dis­closed Tues­day in its sec­ond-quar­ter earn­ings.

The ter­mi­na­tion of MBL949 — which the com­pa­ny said was a GDF-15 ag­o­nist — was one of two cuts No­var­tis made since the last quar­ter­ly up­date. The oth­er was NIS793 in metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma, “based on ben­e­fit-risk as­sess­ment.” A Phase II study of NIS793 in col­orec­tal can­cer will con­tin­ue.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN